BR0202252A - Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease - Google Patents

Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease

Info

Publication number
BR0202252A
BR0202252A BR0202252-4A BR0202252A BR0202252A BR 0202252 A BR0202252 A BR 0202252A BR 0202252 A BR0202252 A BR 0202252A BR 0202252 A BR0202252 A BR 0202252A
Authority
BR
Brazil
Prior art keywords
administration
hiv protease
protease inhibitors
pharmaceutical compositions
pharmaceutical composition
Prior art date
Application number
BR0202252-4A
Other languages
English (en)
Inventor
Ogari De Castro Pacheco
Elisa Mannochio De Souza Russo
Walter Freire Torres Russo
Original Assignee
Cristalia Prod Quimicos Farm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm filed Critical Cristalia Prod Quimicos Farm
Priority to BR0202252-4A priority Critical patent/BR0202252A/pt
Priority to AU2003232535A priority patent/AU2003232535A1/en
Priority to EP03759791.1A priority patent/EP1513512B1/en
Priority to CNB038164647A priority patent/CN1289076C/zh
Priority to PCT/BR2003/000076 priority patent/WO2003105826A2/en
Priority to US10/517,453 priority patent/US7632853B2/en
Publication of BR0202252A publication Critical patent/BR0202252A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA SOLúVEL ESTáVEL PARA ADMINISTRAçãO DE INIBIDORES DA HIV PROTEASE E PROCESSO DE OBTENçãO DE COMPOSIçõES FARMACêUTICAS CONCENTRADAS PARA A ADMINISTRAçãO DE INIBIDORES DA HIV PROTEASE". A presente invenção descreve uma composição farmacêutica solúvel estável para a administração de inibidores da HIV protease. Mais especificamente a composição compreende uma solução de um inibidor da HIV protease em uma combinação de solventes orgânicos farmacêuticos adequados, um surfatante e um ampliador de biodisponibilidade. é descrito também um processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da HIV protease. A composição da presente invenção é adequada a obtenção de soluções orais para a administração de drogas ativas e ao encapsulamento em cápsulas de gelatina dura ou cápsulas de gelatina mole.
BR0202252-4A 2002-06-12 2002-06-12 Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease BR0202252A (pt)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0202252-4A BR0202252A (pt) 2002-06-12 2002-06-12 Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
AU2003232535A AU2003232535A1 (en) 2002-06-12 2003-06-12 "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors."
EP03759791.1A EP1513512B1 (en) 2002-06-12 2003-06-12 Soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors.
CNB038164647A CN1289076C (zh) 2002-06-12 2003-06-12 包含利托那韦的可溶性稳定药物组合物及制备浓缩的药物组合物的方法
PCT/BR2003/000076 WO2003105826A2 (en) 2002-06-12 2003-06-12 "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors."
US10/517,453 US7632853B2 (en) 2002-06-12 2003-06-12 Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR0202252-4A BR0202252A (pt) 2002-06-12 2002-06-12 Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease

Publications (1)

Publication Number Publication Date
BR0202252A true BR0202252A (pt) 2004-06-29

Family

ID=29721217

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0202252-4A BR0202252A (pt) 2002-06-12 2002-06-12 Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease

Country Status (6)

Country Link
US (1) US7632853B2 (pt)
EP (1) EP1513512B1 (pt)
CN (1) CN1289076C (pt)
AU (1) AU2003232535A1 (pt)
BR (1) BR0202252A (pt)
WO (1) WO2003105826A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
WO2012010942A2 (en) 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
US9093803B2 (en) * 2012-09-07 2015-07-28 Apple Inc. Plug connector

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
TR199701541T1 (xx) 1995-06-06 1998-03-21 F.Hoffmann-La Roche Ag Proteinaz engelleyici ve tekli gliserid i�eren farmas�tik bile�im.
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
AU8145198A (en) 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
CN1668292A (zh) 2005-09-14
WO2003105826A3 (en) 2004-02-19
WO2003105826A2 (en) 2003-12-24
US7632853B2 (en) 2009-12-15
EP1513512A2 (en) 2005-03-16
EP1513512B1 (en) 2013-07-31
CN1289076C (zh) 2006-12-13
WO2003105826B1 (en) 2004-03-25
AU2003232535A1 (en) 2003-12-31
EP1513512A4 (en) 2011-03-30
US20050250764A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
AR023228A1 (es) Composiciones en espuma estables
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
BR9714310A (pt) Composição farmacêutica
BR0307524A (pt) Composição farmacêutica para inibidores de protease viral de hepatite c
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
PT1008588E (pt) Derivados da 11,15-o-diaklquil-prostaglandina e processo de producao dos mesmos e farmaco que os contem como ingrediente activo
AR034691A1 (es) Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende
WO1999033792A3 (en) Prodrugs os aspartyl protease inhibitors
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
EP1944300A3 (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CA2414063A1 (en) Highly concentrated stable meloxicam solutions
NO20044487L (no) Kombinasjon av organiske forbindelser
CL2008003324A1 (es) Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis.
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
ATE337016T1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
BR0302523A (pt) Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
WO2003092655A3 (de) Verwendung von wirkstoffmischungen mit azelainsaure und glycyrrhetinsaure als anti-aknemittel
BR0202252A (pt) Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
ES2189080T3 (es) Derivados de creatina para el asma.
BR0312004A (pt) Composições de aerossol transdérmicas
HUP0105359A2 (hu) Benzamidszármazékok és az azokat tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]